Live Breaking News & Updates on Jiaxin Niu

Stay updated with breaking news from Jiaxin niu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic. ....

United States , University Of Chicago , University Of North Carolina , North Carolina , New York , France General , Chapel Hill , United Kingdom , David Rolando , Jared Weiss , Septimiu Murgu , Brandon Owens , Paul Chang , Tanguy Seiwert , Aditya Joolori , Omari Vivar , Siddharth Sheth , Colette Shen , Laurent Wormser , George Yang , Trevor Hackman , Jimmy Caudell , Jiaxin Niu , Kedar Kirtane , Kevin Gardner , Jessica Frakes ,

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 ...

New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent ....

University Of Chicago , United States , Chapel Hill , North Carolina , United Kingdom , New York , France General , University Of North Carolina , Kedar Kirtane , Jessica Frakes , Shetal Patel , Siddharth Sheth , David Rolando , Aditya Joolori , Trevor Hackman , Omari Vivar , Paul Chang , Jiaxin Niu , Septimiu Murgu , Colette Shen , George Yang , Tanguy Seiwert , Jared Weiss , Jimmy Caudell , University Of Texas Md Anderson Cancer Center , Moffitt Cancer Center ,

'Unprecedented' Results With RP1 Plus Nivolumab in Non-Melanoma Skin Cancers

RP1 plus nivolumab can produce durable responses in patients with non-melanoma skin cancer of the head and neck, a phase 2 study suggests. ....

United States , Jiaxin Niu , Banner Md Anderson Cancer Center , Neck Cancers , Cancer Center ,

Novel Therapies Active in Head and Neck Cancers

High response rate with oncolytic virus plus immunotherapy in cutaneous lesions ....

United States , Charles Bankhead , Jiaxin Niu , University Of Texas Md Anderson Cancer Center , Banner Md Anderson Cancer Center , Cancer Center , Multidisciplinary Head , Neck Cancers Symposium , May Cho , Medpage Today , Neck Cancers ,